BiotechTube

ACR-2316

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Specific Advanced Solid Tumors

Conditions

Specific Advanced Solid Tumors

Trial Timeline

Oct 8, 2024 → Dec 12, 2026

NCT ID
NCT06667141

About ACR-2316

ACR-2316 is a phase 1 stage product being developed by Acrivon Therapeutics for Specific Advanced Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06667141. Target conditions include Specific Advanced Solid Tumors.

What happened to similar drugs?

0 of 1 similar drugs in Specific Advanced Solid Tumors were approved

Approved (0) Terminated (0) Active (1)
🔄Nasal Glucagon (NG) + Glucagon IMEli LillyPhase 3

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06667141Phase 1Recruiting

Competing Products

18 competing products in Specific Advanced Solid Tumors

See all competitors
ProductCompanyStageHype Score
DJ-927 + capecitabineDaiichi SankyoPhase 1
29
E7389 + E7389 + E7389EisaiPhase 1
29
bevacizumab + enzastaurin hydrochlorideEli LillyPhase 1
29
Nasal Glucagon (NG) + Glucagon IMEli LillyPhase 3
40
SHR-1916Jiangsu Hengrui MedicinePhase 1
21
Quetiapine XRAstraZenecaPhase 2
35
PI3K inhibitor BKM120 + docetaxelNovartisPhase 1
29
capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)NovartisPhase 1
29
warfarinNovartisPhase 1
29
BEZ235 + MEK162PfizerPhase 1
29
Ixabepilone + SunitinibPfizerPhase 1
29
ixabepilone + lapatinib ditosylateBristol Myers SquibbPhase 1
21
carboplatin + irinotecan hydrochlorideBristol Myers SquibbPhase 1
29
intoplicineSanofiPhase 1
29
apomineSanofiPhase 1
29
apomineSanofiPhase 1
29
SorafenibBayerPhase 2
32
NKTR-214Nektar TherapeuticsPhase 1/2
26